Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
Authors:
- 2 March 2016
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 32 (5) , 959-965
Abstract
Background: Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen-receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2−) breast cancer. This report assesses the impact of palbociclib in combination with letrozole versus letrozole alone on patient-reported outcomes of pain.Methods: Palbociclib was evaluated in an open-label, randomized, phase II study (PALOMA-1/TRIO-18) among postmenopausal women with advanced ER+/HER2− breast cancer who had not received prior systemic treatment for their advanced disease. Patients received continuous oral letrozole 2.5 mg daily alone or the same letrozole dose and schedule plus oral palbociclib 125 mg, given once daily for 3 weeks followed by 1 week off over repeated 28-day cycles. The primary study endpoint was investigator-assessed progression-free survival in the intent-to-treat population and these results have re...Keywords
This publication has 10 references indexed in Scilit:
- Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2015
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015
- Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort studyThe Breast, 2014
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation TreatmentClinical Breast Cancer, 2013
- Aromatase inhibitor-induced arthralgia: a reviewAnnals of Oncology, 2013
- Quality of life assessments in advanced breast cancer: should there be more consistency?European Journal of Cancer Care, 2012
- Symptom Management in Metastatic Breast CancerThe Oncologist, 2011
- Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in DenmarkBMC Cancer, 2011
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009